【中图分类号】R735.34【文献标识码】A DOI：10.12114/j.issn.1007-9572.2024.0203

    【Abstract】Background38.4%ofpatients withcolorectal cancerdied from non-cancerdisease，withcardiovascular disease being the most important cause，accounting for 20.3% of the total deaths. Cardiovascular toxicity associated with targeted therapyis notuncommon，mostnotably hypertension.ObjectiveThestudyaimedtodeterminetheoverallincidenceandrisk ofcardiovasculartoxicityassociatedwithfruquintinib inmetastaticcolorectal cancer.MethodsWesearchedCNKI，Wanfang Data，CBM，PubMed，Embase，WebofScienceandCochraneLibrarydatabases forsingle-armclinicaltrialsandrandomized controlledtrials(RCTs)relevanttofuquintinibtherapyinpatientswithmetastaticcolorectalcancer.Thesearchtimelimit wasfromtheestablishmentofthedatabases toMay2O24.Literaturescreening，dataextraction，andqualityevaluationwereperformed independentlybytwoinvestigators.The meta-analysis wasconductedusingR4.3.3software.ResultsEightarticles involvingsix single-armclinical trialsand threerandomizedcontroledtrialswere included.The meta-analysisresultsshowedthattheincidence rates of all-grade hypertension and hemorrhage were 35 % (95%CI=0.25-0.45) and 24% (95%CI=0.10-0.37) ......